CompanyGraph
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
300357 · SZSE · China
wolwobiotech.comFinancials as of FY2025
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $1.52B, above the global median of $1.18B
- FinancialsHigh structural barrier to entry
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.77%Above 5Y avg (0.72%)
Annual Rate
CNY 0.15Paid annual
Payout Ratio
27.6%Sustainable
Last Ex-Dividend
Jul 9, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.18BCNY1.52B · vs all stocks (USD)
Trailing P/E
24.31xRevenue (TTM)
1.09BCNY163.00M · vs all stocks (USD)
Profit Margin
38.21%Beta
0.3670xvs all stocks
52-Week Change
-31.78%vs all stocks
Market Capitalization
10.18BCNY1.52B · vs all stocks (USD)
Enterprise Value
8.84BCNY1.32B · vs all stocks (USD)
Trailing P/E
24.31xForward P/E
19.07xPrice to Sales (TTM)
9.32xPrice to Book (MRQ)
3.70xEnterprise to Revenue
8.09xEnterprise to EBITDA
18.54xGross Margin
95.34%Profit Margin
38.21%Operating Margin
40.39%Return on Assets (TTM)
8.99%Return on Equity (TTM)
15.03%Revenue (TTM)
1.09BCNY163.00M · vs all stocks (USD)
Revenue per Share (TTM)
2.09CNYUpdated Sep 20, 2026Quarterly Revenue Growth
2.20%Gross Profit (TTM)
1.04BCNY155.38M · vs all stocks (USD)
EBITDA (TTM)
393.39MCNY58.70M · vs all stocks (USD)
Net Income (TTM)
417.38MCNY62.28M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-8.20%Operating Cash Flow (TTM)
412.19MCNY61.51M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
218.27MCNY32.57M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1500CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.77%vs all stocks
5-Year Average Dividend Yield
0.72%vs all stocks
Payout Ratio
27.60%Minority Interest (Equity)
92.27MCNYFY2025 · Dec 31, 2025Revenue
1.06BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
50.58MCNYFY2025 · Dec 31, 2025Gross Profit
1.01BCNYFY2025 · Dec 31, 2025Operating Income
414.41MCNY61.84M · vs all stocks (USD)
Pre-tax Income
432.71MCNYFY2025 · Dec 31, 2025Income Tax Expense
64.62MCNYFY2025 · Dec 31, 2025Net Income
368.09MCNYFY2025 · Dec 31, 2025EBIT
433.50MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
490.80MCNYFY2025 · Dec 31, 2025Research & Development
117.10MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
240.34MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.56MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
23.72MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
792.85KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.7276CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.7276CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
523.56MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
523.56MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
368.09MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
12.85MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
382.47MCNYFY2025 · Dec 31, 2025Free Cash Flow
263.13MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
120.06MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
368.09MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.50MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
9.03MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.86MCNYFY2025 · Dec 31, 2025Capital Expenditures
-119.35MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.22BCNYFY2025 · Dec 31, 2025Sale of Investments
1.11BCNYFY2025 · Dec 31, 2025Other Investing Activity
-32.95MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-271.88MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
20.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-27.63MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-115.30MCNYFY2025 · Dec 31, 2025Other Financing Charges
-6.18MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-129.11MCNYFY2025 · Dec 31, 2025Shares Outstanding
523.58MSharesUpdated Sep 20, 2026Float Shares
263.14MSharesUpdated Sep 20, 2026% Held by Insiders
52.13%vs all stocks
% Held by Institutions
8.45%vs all stocks
Total Cash (MRQ)
1.45BCNY216.83M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.77CNYUpdated Sep 20, 2026Total Debt (MRQ)
18.29MCNY2.73M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0064xCurrent Ratio (MRQ)
9.14xBook Value per Share (MRQ)
5.26CNYUpdated Sep 20, 2026Total Assets
2.90BCNY432.35M · vs all stocks (USD)
Total Current Assets
1.76BCNYFY2025 · Dec 31, 2025Total Liabilities
185.67MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.14BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
41.10MCNYFY2025 · Dec 31, 2025Total Current Liabilities
144.57MCNYFY2025 · Dec 31, 2025Cash
797.22MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
797.22MCNYFY2025 · Dec 31, 2025Other Short-term Investments
560.23MCNYFY2025 · Dec 31, 2025Accounts Receivable
163.22MCNYFY2025 · Dec 31, 2025Inventory
54.76MCNYFY2025 · Dec 31, 2025Accounts Payable
31.41MCNYFY2025 · Dec 31, 2025Short-term Debt
9.09MCNYFY2025 · Dec 31, 2025Long-term Debt
9.32MCNYFY2025 · Dec 31, 2025Common Stock (Book)
523.58MCNYFY2025 · Dec 31, 2025Retained Earnings
1.70BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.71BCNY404.64M · vs all stocks (USD)
52-Week Low
18.65CNYUpdated Sep 20, 202652-Week High
35.84CNYUpdated Sep 20, 202652-Week Change
-31.78%vs all stocks
Beta
0.3670xvs all stocks
50-Day MA
23.20CNYUpdated Sep 20, 2026200-Day MA
25.32CNYUpdated Sep 20, 2026Avg 10-Day Volume
10.82MSharesUpdated Sep 20, 2026Avg 30-Day Volume
12.64MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.8000CNYUpdated Sep 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.50
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $1.52B, above the global median of $1.18BNotable
Market cap (USD): 1,519,613,027.136Global Median: 1,180,223,658.953
Levered free cash flow is $32.57M, above the global median of $18.73MNotable
Levered free cash flow (USD): 32,570,757.942Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Balance Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tyra Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Alphatec Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hangzhou Shunwang Technology Co., Ltd.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesPrice Below Mean With Profitability And Book Value
Zhejiang Sanmei Chemical Industry Co., Ltd.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesPrice Below Mean With Profitability And Book Value
Birlasoft Ltd.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesPrice Below Mean With Profitability And Book Value